Royalty Pharma plc (RPRX)
NMS · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Incyte Corporation
Recent press releases
April 2026
Royalty Pharma (RPRX) Reports $2.2B Revenue, Executes $1.5B in New Deals
# 🧾 What This Document Is This is Royalty Pharma's **Annual Report to Shareholders (ARS)**. Think of it as the company's "year in review" magazine, packaged for investors. It’s not just a dry legal filing; it’s designed to tell the story of their past year, showcase their financial health, and expl
Royalty Pharma Sets June 4 Meeting to Vote on Directors and Pay
# 🧾 What This Document Is This is a **proxy statement** (DEF 14A) for Royalty Pharma's 2026 Annual General Meeting. Think of it as an information packet and voting guide for shareholders. It explains what will be voted on at the meeting, provides details about the company's leadership and pay, and
SEC filings
All filings →Insider trades
All insider trades →Royalty Pharma plc has no reported insider trades in the last 90 days.